Affordable Access

Publisher Website

PROTECTION OF VOLUNTEERS AGAINST CHALLENGE WITH A/HONG KONG/68 INFLUENZA VIRUS BY A NEW ADAMANTANE COMPOUND

Authors
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
299
Issue
7759
Identifiers
DOI: 10.1016/s0140-6736(72)91220-2
Disciplines
  • Medicine

Abstract

Abstract Volunteers with low antibody titres to A/Hong Kong/68 virus were treated orally with 1'-methyl spiro (adamantane-2,3'-pyrrolidine) maleate (1:1) or with inert placebo prior to challenge with partly attenuated virus in a double-blind trial. The volunteers in the drug-treated group produced fewer clinical symptoms, antibody rises, and virus excretions than those in the placebo-treated group. Also, members of the drug-treated group who had laboratory evidence of infection experienced milder clinical symptoms than their counterparts of the placebo-treated group. There may be a place for this drug in the prophylaxis and therapy of type-A influenza.

There are no comments yet on this publication. Be the first to share your thoughts.